ATE283056T1 - Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere - Google Patents

Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere

Info

Publication number: ATE283056T1
Authority: AT; Austria
Prior art keywords: hydroxyacids; oligomers; linear; ketone; cyclic oligomers
Prior art date: 1998-07-22

Application number

AT99935846T

Other languages

English (en)

Inventor

David P Martin

Oliver P Peoples

Simon F Williams

Luhua Zhong

Original Assignee

Metabolix Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-22

Filing date

1999-07-22

Publication date

2004-12-15

1999-07-22 Application filed by Metabolix Inc filed Critical Metabolix Inc

2004-12-15 Application granted granted Critical

2004-12-15 Publication of ATE283056T1 publication Critical patent/ATE283056T1/de

Links

WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 abstract 5
REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 abstract 4
125000004122 cyclic group Chemical group 0.000 abstract 4
150000002576 ketones Chemical class 0.000 abstract 4
239000008280 blood Substances 0.000 abstract 2
210000004369 blood Anatomy 0.000 abstract 2
235000015872 dietary supplement Nutrition 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 abstract 1
OXSSIXNFGTZQMZ-UHFFFAOYSA-N 3-hydroxyheptanoic acid Chemical compound CCCCC(O)CC(O)=O OXSSIXNFGTZQMZ-UHFFFAOYSA-N 0.000 abstract 1
HPMGFDVTYHWBAG-UHFFFAOYSA-N 3-hydroxyhexanoic acid Chemical compound CCCC(O)CC(O)=O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 abstract 1
230000036765 blood level Effects 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000016097 disease of metabolism Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
150000001261 hydroxy acids Chemical class 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
230000003880 negative regulation of appetite Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
235000016236 parenteral nutrition Nutrition 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000002459 sustained effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Neurology (AREA)
Zoology (AREA)
Animal Husbandry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Birds (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99935846T 1998-07-22 1999-07-22 Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere ATE283056T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9376098P	1998-07-22	1998-07-22
PCT/US1999/016614 WO2000004895A2 (en)	1998-07-22	1999-07-22	Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers

Publications (1)

Publication Number	Publication Date
ATE283056T1 true ATE283056T1 (de)	2004-12-15

Family

ID=22240563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99935846T ATE283056T1 (de)	1998-07-22	1999-07-22	Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere

Country Status (10)

Country	Link
US (1)	US6380244B2 (de)
EP (1)	EP1098655B1 (de)
JP (2)	JP2002521330A (de)
AT (1)	ATE283056T1 (de)
AU (1)	AU755348B2 (de)
CA (1)	CA2338090C (de)
DE (1)	DE69922206T2 (de)
ES (1)	ES2234276T3 (de)
MX (1)	MXPA01000632A (de)
WO (1)	WO2000004895A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090253781A1 (en) *	2002-05-24	2009-10-08	Btg International Limited	Therapeutic compositions
US6323237B1 (en)	1997-03-17	2001-11-27	Btg International Limited	Therapeutic compositions
EP1123094B1 (de)	1998-09-15	2007-04-11	Btg International Limited	Therapeutische zusammenstellungen
US6835750B1 (en)	2000-05-01	2004-12-28	Accera, Inc.	Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
PT1292294E (pt)	2000-05-01	2009-06-01	Accera Inc	Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
US6410063B1 (en) *	2000-06-13	2002-06-25	Hill's Pet Nutrition, Inc.	Composition and method
US7407778B2 (en) *	2002-02-07	2008-08-05	Pettegrew Jay W	Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) *	2002-02-07	2010-04-20	Pettegrew Jay W	Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1641806B1 (de) *	2003-05-29	2009-07-29	Jay W. Pettegrew	Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US20060257842A1 (en) *	2003-05-29	2006-11-16	Pettegrew Jay W	Cryopreservation media and molecules
CA2527940C (en) *	2003-06-03	2016-03-22	Richard L. Veech	Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
EP1661574B1 (de) *	2003-09-01	2017-04-19	Earthus, Inc.	Beta-hydroxy-kurz- bis mittelkettiges fettsäure-polymer
GB0420856D0 (en) *	2004-09-20	2004-10-20	Ketocytonyx Inc	Cns modulators
WO2006020137A2 (en) *	2004-07-16	2006-02-23	Ketocytonyx Inc.	Oligomeric compounds
WO2006020179A2 (en) *	2004-07-20	2006-02-23	Ketocytonyx Inc.	Oligomeric ketone compounds
WO2006012490A2 (en) *	2004-07-23	2006-02-02	Ketocytonyx Inc.	Ketogenic saccharides
US20070281892A1 (en) *	2004-09-21	2007-12-06	Martin Keith F	Dopaminergic Mimetics
US20070197645A1 (en) *	2004-09-21	2007-08-23	Martin Keith F	Treatment of adhd
GB0427145D0 (en) *	2004-12-10	2005-01-12	Ketocytonyx Inc	Compositions for use in surgery
CN100344280C (zh) *	2005-08-01	2007-10-24	清华大学	3－羟基丁酸及其衍生物的新用途
DK2500017T3 (da) *	2006-04-03	2017-11-06	Accera Inc	Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
US7807718B2 (en) *	2006-06-30	2010-10-05	Sami A. Hashim	Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US8758740B2 (en)	2007-03-30	2014-06-24	Earthus, Inc	Composition for promoting ketone body production
EP2650382B9 (de)	2007-07-31	2016-04-13	Accera, Inc.	Verwendung genomischer und ketogener Verbindungen zur Behandlung von beeinträchtigten kognitiven Funktionen
WO2009089144A1 (en)	2008-01-04	2009-07-16	Isis Innovation Limited	Ketone bodies and ketone body esters as blood lipid lowering agents
EP2303036A1 (de) *	2008-07-03	2011-04-06	Accera, Inc.	Acetoacetat-monoglyzeride und derivate zur behandlung neurologischer erkrankungen
US8105809B2 (en) *	2008-07-03	2012-01-31	Accera, Inc.	Enzymatic synthesis of acetoacetate esters and derivatives
US8642654B2 (en) *	2009-04-16	2014-02-04	Isis Innovation Limited	Hydroxybutyrate ester and medical use thereof
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
GB201002983D0 (en)	2010-02-22	2010-04-07	Tdeltas Ltd	Nutritinal composition
WO2014071389A1 (en)	2012-11-05	2014-05-08	Veech Richard L	Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en)	2013-03-12	2013-04-24	Tdeltas Ltd	Compound for use in protecting skin
DK2984066T3 (en)	2013-03-14	2017-05-08	Univ Oxford Innovation Ltd	Process for preparing (R) -hydroxybutyl (R) -3-hydroxybutyrate
BR112015024186B1 (pt) *	2013-03-19	2023-05-09	University Of South Florida	Composições e métodos para produção de cetose de elevação e manutenção
CA2973342A1 (en) *	2014-01-13	2015-10-15	University Of South Florida	Methods of sustaining dietary ketosis and its effects on lipid profile
EP3177284B1 (de)	2014-07-21	2020-01-15	Oulun Yliopisto	Oligomere formen von 3-hydroxybutyrat
US10245242B1 (en)	2017-11-22	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en)	2017-11-22	2021-08-31	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en)	2016-03-11	2021-04-13	Axcess Global Sciences, Llc	R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en)	2017-12-19	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11241403B2 (en)	2016-03-11	2022-02-08	Axcess Global Sciences, Llc	Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en)	2016-03-11	2020-08-11	Axcess Global Sciences, Llc	Mixed salt compositions for producing elevated and sustained ketosis
US10596130B2 (en)	2017-12-19	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en)	2017-12-19	2021-11-30	Axcess Global Sciences, Llc	S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en)	2019-02-13	2021-04-13	Axcess Global Sciences, Llc	Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11026929B2 (en)	2016-04-19	2021-06-08	Keto Patent Group, Inc.	Administration of berberine metabolites
SG11201809211QA (en) *	2016-04-19	2018-11-29	Keto Patent Group Inc	Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11806324B2 (en)	2018-04-18	2023-11-07	Axcess Global Sciences, Llc	Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10925843B2 (en)	2018-04-18	2021-02-23	Axcess Global Sciences, Llc	Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12109182B2 (en)	2016-04-19	2024-10-08	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate and related compounds in humans
US11337945B2 (en)	2016-06-01	2022-05-24	Keto Innovations, Llc	C5 ketone compositions, and related methods, for therapeutic and performance supplementation
US20180057846A1 (en)	2016-08-30	2018-03-01	KetoneAid Inc.	Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20190314307A1 (en) *	2016-12-23	2019-10-17	Katholieke Universiteit Leuven	3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
US12171735B2 (en)	2017-04-19	2024-12-24	Axcess Global Sciences, Llc	Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
US11760963B2 (en)	2017-08-23	2023-09-19	KetoneAid Inc.	Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en)	2017-09-27	2017-11-08	Tdeltas Ltd	Method of treatment
US11202769B2 (en)	2017-11-22	2021-12-21	Axcess Global Sciences, Llc	Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12090129B2 (en)	2017-11-22	2024-09-17	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en)	2017-12-19	2024-04-02	Axcess Global Sciences, Llc	Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
IT201800003441A1 (it)	2018-03-12	2019-09-12	Bio On Spa	Poliidrossialcanoati per l’uso nella prevenzione del cancro colorettale.
US10980772B2 (en)	2018-08-27	2021-04-20	Axcess Global Sciences, Llc	Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en)	2019-02-13	2022-08-23	Axcess Global Sciences, Llc	Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en)	2020-02-06	2022-02-08	Axcess Global Sciences, Llc	Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en)	2018-08-27	2021-09-28	Axcess Global Sciences, Llc	Compositions and methods for delivering cannabidiol and ketone bodies
US10512615B1 (en)	2018-08-27	2019-12-24	Axcess Global Sciences, Llc	Compositions and methods for delivering cannabidiol and ketone bodies
CA3022995C (en) *	2018-06-12	2019-10-15	Ketofibe (9211-3133 Quebec Inc.)	Novel ketogenic compounds, compositions, methods and use thereof
IT201800007524A1 (it) *	2018-07-26	2020-01-26	Bio-On Spa	Poliidrossialcanoati per l'uso nella prevenzione o nel trattamento di una condizione di sovrappeso o di obesita', ovvero di disfunzioni metaboliche correlate a tale condizione.
US11033553B2 (en)	2019-06-21	2021-06-15	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en)	2023-03-10	2024-04-30	Axcess Global Sciences, Llc	Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en)	2019-06-21	2024-12-17	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en)	2019-06-21	2024-04-09	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN114929253A (zh) *	2019-10-10	2022-08-19	美泰拉制药有限公司	包含芫花、威灵仙及天麻的复合生药提取物的用于预防或治疗神经退行性疾病的组合物
CN110776425B (zh) *	2019-10-23	2021-02-26	清华大学	一种(r)-3-羟基丁酸及其低聚物的制备方法
CA3170624A1 (en) *	2020-03-05	2021-09-10	VitaNav, Inc.	Composition of (d)-.beta.-hydroxybutyric acid, (d)-.beta.-hydroxyvalericacid, and (d)-1,3 butanediol as a nutritional supplement and therapeuticagent
US12186297B2 (en)	2020-08-26	2025-01-07	Axcess Global Sciences, Llc	Compositions and methods for increasing lean-to-fat mass ratio
AU2022345781A1 (en)	2021-09-15	2024-03-07	Lingo Sensing Technology Unlimited Company	Systems, devices, and methods for applications for communication with ketone sensors
WO2024155950A2 (en) *	2023-01-20	2024-07-25	Keto Innovations, Llc	C5 ketone compositions and related methods for therapeutic and performance supplementation
WO2025024280A1 (en) *	2023-07-21	2025-01-30	Keto Innovations, Llc	C5 ketone compositions and related methods for treating metabolic dysfunction

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4423072A (en)	1979-12-28	1983-12-27	The University Of Kentucky Research Foundation	Method for improving the metabolic stability and survival of neonatal pigs
US4329359A (en)	1979-12-28	1982-05-11	University Of Kentucky Research Foundation	Method for improving the metabolic stability and survival of newborn pigs
FR2486072A1 (fr) *	1980-07-03	1982-01-08	Solvay	Procede pour la fabrication de l'acide b-hydroxybutyrique et de ses oligocondensats
US4563354A (en)	1983-10-26	1986-01-07	Kabivitrum Ab	Oil-in-water emulsion for parenteral administration
AU602772B2 (en)	1987-04-22	1990-10-25	Baxter International Inc.	Lipid emulsion and method for intravenous infusion
BE1001209A3 (fr) *	1987-11-19	1989-08-22	Solvay	Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) *	1987-11-19	1992-06-30	Henri Brunengraber	Composition for parenteral and oral nutrition
SE8705035L (sv)	1987-12-17	1989-06-18	Kaernerud Lars Haelsoprod	Anvaendning av alkylglycerol
CA1334575C (en)	1988-07-26	1995-02-28	Atsushi Hiraide	Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts
SE8803142L (sv)	1988-09-07	1990-03-08	Kabivitrum Ab	Nya energisubstrat
SE8803141L (sv)	1988-09-07	1990-03-08	Kabivitrum Ab	Naeringsmedel foer maenniskor och djur
AU634537B2 (en)	1989-03-30	1993-02-25	Kabi Pharmacia Ab	Pharmaceutical lipid composition for parenteral nutrition
JP2885261B2 (ja)	1993-05-17	1999-04-19	三菱瓦斯化学株式会社	３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤
WO1995009144A1 (en) *	1993-09-30	1995-04-06	Eastman Chemical Company	Nutritive water soluble glycerol esters of hydroxy butyric acid
AU1560095A (en) *	1994-01-06	1995-08-01	Metabolix, Inc.	Methods for synthesizing oligomers containing hydroxy acid units
US6083729A (en)	1995-10-26	2000-07-04	Metabolix, Inc.	Methods for isolating polyhydroxyalkanoates from plants
JP4598203B2 (ja)	1995-12-01	2010-12-15	ビーティージー・インターナショナル・リミテッド	脳機能改善剤
KR100839689B1 (ko)	1997-03-17	2008-06-18	비티지 인터내셔널 리미티드	치료용 조성물
AU748733B2 (en) *	1998-01-07	2002-06-13	Metabolix, Inc.	Animal nutrition compositions

1999
- 1999-07-22 DE DE69922206T patent/DE69922206T2/de not_active Expired - Lifetime
- 1999-07-22 US US09/359,086 patent/US6380244B2/en not_active Expired - Lifetime
- 1999-07-22 AU AU51231/99A patent/AU755348B2/en not_active Ceased
- 1999-07-22 MX MXPA01000632A patent/MXPA01000632A/es unknown
- 1999-07-22 WO PCT/US1999/016614 patent/WO2000004895A2/en active IP Right Grant
- 1999-07-22 CA CA002338090A patent/CA2338090C/en not_active Expired - Fee Related
- 1999-07-22 AT AT99935846T patent/ATE283056T1/de not_active IP Right Cessation
- 1999-07-22 EP EP99935846A patent/EP1098655B1/de not_active Expired - Lifetime
- 1999-07-22 ES ES99935846T patent/ES2234276T3/es not_active Expired - Lifetime
- 1999-07-22 JP JP2000560888A patent/JP2002521330A/ja not_active Withdrawn
2011
- 2011-10-21 JP JP2011231730A patent/JP2012072148A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MXPA01000632A (es)	2002-05-06
JP2012072148A (ja)	2012-04-12
AU755348B2 (en)	2002-12-12
CA2338090A1 (en)	2000-02-03
EP1098655B1 (de)	2004-11-24
US20020013339A1 (en)	2002-01-31
DE69922206T2 (de)	2005-11-24
DE69922206D1 (de)	2004-12-30
EP1098655A2 (de)	2001-05-16
CA2338090C (en)	2009-07-14
AU5123199A (en)	2000-02-14
JP2002521330A (ja)	2002-07-16
ES2234276T3 (es)	2005-06-16
WO2000004895A3 (en)	2000-04-27
US6380244B2 (en)	2002-04-30
WO2000004895A2 (en)	2000-02-03

Publication	Publication Date	Title
ATE283056T1 (de)	2004-12-15	Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
Guo et al.	2020	The role of nutrition in the prevention and intervention of type 2 diabetes
Bistrian et al.	1977	Effect of a protein-sparing diet and brief fast on nitrogen metabolism in mildly obese subjects
KR100839689B1 (ko)	2008-06-18	치료용 조성물
JP2002521330A5 (de)	2006-08-31
Sobotka et al.	2009	Basics in clinical nutrition: Metabolic response to injury and sepsis
Leonard	2020	The physiology of ketosis and the ketogenic diet
Boden	2009	High or Low Carbohydrate Diets: Which is better for weight loss, insulin resistance and fatty livers?
US8609165B1 (en)	2013-12-17	Dietary supplement for optimizing glucose levels, increasing energy, and improving general health
Pryme et al.	1996	Dietary phytohaemagglutinin slows down the proliferation of a mouse plasmacytoma (MPC-11) tumour in Balb/c mice
AU2020356255A1 (en)	2022-03-03	Compositions and methods using adenosylcobalamin
Lu et al.	2020	The effects of nutritional ketosis induced by Bigu-herbs regimen and ketogenic diet on diseases and aging
Chereshnev et al.	2020	Global ageing: challenges and perspectives
Barański et al.	2024	The role of the ketogenic diet in the treatment and prevention of diseases: A literature review
Raja et al.	2023	Influence of Ketogenic Diet on Diabetes
Hite et al.	2011	Low-carbohydrate diet scores and risk of type 2 diabetes in men
Landes et al.	2022	Amplifying the human body’s innate “rapid response” systems to inflammation and oxidative stress
Kozjek et al.	2025	Nutrition for optimising immune function and recovery from injury in sports
Zhao	2024	The impact of high-fiber diet on diabetes and obesity in middle-aged adults
Goto	0	The Skinny on Intermittent Fasting
CN113712992A (zh)	2021-11-30	含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用
Roncari	1987	Individual variations in energy utilized for biomechanical processes and molecular mobility account for diverse susceptibility to obesity
Kim	2015	Dietary fatty acids on glycemic control and cardiovascular risk
Robert	2010	Aging in the 21st century
O'Brien et al.	0	Want To Be Running Marathons at 100? Then Try Intermittent Fasting!

Legal Events

Date	Code	Title	Description
2005-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties